ACI’s mission is defined in three words: opportunity, compassion and progress. We aim to create opportunity: for pet owners to have access to cutting edge treatment options for their pets, for our network veterinarians to offer investigational treatments to their clients, and for animal health companies to learn whether their drugs and products are safe and effective. We are driven by our compassion for companion animals. As a group of veterinarians, veterinary technicians, scientists, and support staff, we seek to improve and extend the lives of pet animals. Further, we deliver progress to the veterinary community, specifically contributing to scientificallyvalidated, treatments and other products, and the body of knowledge of disease in companion animals.
ACI has successfully designed and implemented trials that have tested novel chemotherapeutic agents, immunotherapeutic strategies using cytokine and tumor vaccines, anti-angiogenic therapies for dogs and cats with cancer, and specialized diets. Trials have been along the spectrum from pilot and proof-of-concept studies to pivotal trials submitted for regulatory authority approval. Trials are managed consistent with good clinical practice (GCP) standards in accordance with VICH guidelines.
Clinical trials organized by ACI have primarily focused on testing new cancer treatments through our network of veterinary oncologists and radiation oncologists. ACI draws upon a large caseload of veterinary cancer patients through its network sites, as well as academic veterinary teaching hospitals, allowing for the rapid accrual of cases and high quality clinical data.
In the past few years, ACI has expanded its efforts through our Specialty Network to include other complex medical conditions including inflammatory and metabolic disease, cardiovascular disease, arthritis, and other age-related medical problems. We are ready to start clinical trials with a single contract, providing multisite, pivotal or non-pivotal studies and commercialization support.